Tuesday, October 3, 2023
Tuesday, October 3, 2023

Contact: 561.316.3330

Inspira Technologies Appoints Dr Adi Rizansky Nir, PhD as CMO

Inspira Technologies OXY B.H.N. Ltd. (Nasdaq: IINN) (Nasdaq: IINNW) (the “Company” or “Inspira Technologies”), a company aiming to revolutionize acute respiratory care, has announced the appointment of Dr. Adi Rizansky Nir, PhD to the position of Chief Medical Officer (“CMO”). Dr. Nir brings a wealth of expertise and a distinguished track record in the field of medicine and healthcare administration to the Company.

As CMO, Dr. Nir will play a critical role in overseeing and guiding Inspira’s medical operations and strategic initiatives. With an unwavering commitment to patient care, innovation, and clinical excellence, we believe that Dr. Nir is poised to make a transformative impact on the healthcare landscape within our organization and on the broader medical community.

With many years of experience in both clinical practice development and healthcare leadership, Dr. Nir has a deep understanding of the challenges and opportunities in today’s rapidly evolving healthcare industry. Throughout her career, Dr. Nir has demonstrated exceptional leadership, has built out operational efficiencies, and has fostered collaboration and teamwork among healthcare professionals.

Dr. Nir holds a PhD in Health Economics, an MSc. in Molecular Biology, and an MBA from the Hebrew University of Jerusalem . Dr. Nir has made significant contributions to clinical research and advancements in multiple therapeutic areas. Dr. Nir has extensive experience in clinical strategy implementation and in the scientific and commercial evaluation of R&D assets. Dr. Nir specializes in health economics, market evaluation, and the financial valuation of pharmaceutical assets, medical devices, and digital health products. She also has vast experience in managing strategic planning, negotiations, in-and-out-licensing, and comprehensive due diligence processes, of which she has conducted many. Dr. Nir joined the company in 2021 and has significantly contributed to the Company’s clinical strategy and product development activities.

On the appointment, Inspira Technologies’ CEO, Dagi Ben Noon said, “We are thrilled to have Dr. Nir as our new CMO. With her vast experience and exceptional leadership skills, we are confident that she will further strengthen our commitment to delivering high-quality care and advancing our organization’s mission of improving treatments for Acute Respiratory Care. Inspira Technologies has an important year ahead with our planned U.S. Food and Drug Administration (FDA) submission, clinical trial planning, and clinical development. Dr. Nir’s appointment to the position of CMO will be key in successfully advancing the potential regulatory approval and clinical adoption of our products.”

In her new role, Dr. Nir will collaborate closely with the Company’s executive leadership team, medical staff, and Scientific Advisory Board to develop and implement innovative strategies that enhance patient outcomes, streamline clinical operations, and promote evidence-based practices.

Dr. Nir expressed her enthusiasm about her appointment, stating, “I am honored to be appointed to the position of CMO. I look forward to contributing to its mission of developing exceptional healthcare treatments, aimed at revolutionizing the treatment offered to acute respiratory patients worldwide. I also look forward to directing the development of clinical strategies and planning the Company’s pipeline with the dedicated and talented team of healthcare leaders to drive innovation, improve patient outcomes, and elevate the standard of care in this growing medical sector.”

Please join us in welcoming Dr. Nir to her new position in our Inspira Technologies family. With her expertise and dedication, we are confident that our organization will continue to thrive in delivering treatment solutions to patients.

Medical Device News Magazinehttps://infomeddnews.com
Our publication is dedicated to bringing our readers the latest medical device news. We are proud to boast that our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall purpose and objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.


Broken String Biosciences Strengthens Senior Leadership Team

Bringing significant expertise in their respective fields, Vincent Smith, PhD and Jessica Rich appointments are a key part of Broken String’s strategy to deliver on its Series A goals, which include the continued development of its INDUCE-seq™ DNA break-mapping platform and acceleration of its commercial expansion across global markets.

New Chief Sales Officer at Encare with Focus on Continued Global Expansion

The HealthTech company Encare has recruited Lotta Sellén as the new Chief Sales Officer (CSO). Lotta Sellén has solid experience in the pharmaceutical, healthcare and HealthTech industries.

CorWave Appoints Magalie Durrèche as Chief Financial Officer

Magalie Durrèche will oversee the financial management and participate in the strategic planning and fundraising of CorWave, a company developing and manufacturing a blood pump based on breakthrough technology. She succeeds Zina Hamoumi, who served as Chief Financial Officer for five years before deciding to focus on other projects.

Veracyte Names Dr Phillip G Febbo Chief Scientific Officer and Chief Medical Officer

“Phil G Febbo is an exceptional leader with a strong track record of driving successful commercialization of molecular tests through evidence development, guideline inclusion and key opinion leader support,” said Mr. Stapley. “His experience and expertise will be critical to further enhancing our ability to serve our customers and, ultimately, to transforming cancer care for patients all over the world.”

GrayMatters Health Expands US Executive Team, Including Appointment of Dr Aron Tendler as Chief Medical Office

Dr Aaron Tendler is a board-certified psychiatrist based in Palm Beach, Florida, bringing over 20 years of experience as an industry leader researching novel treatments for mental health disorders.

By using this website you agree to accept Medical Device News Magazine Privacy Policy